Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
veliparib · 1 trial · 1 indication
Safety and tolerability will be assessed through clinical laboratory tests, electrocardiograms (ECGs), vital signs, physical exams and adverse event assessments
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| veliparib | DRUG | Dose orally twice daily for 7 days, consecutively, every cycle |
| Temozolomide | DRUG | Dose orally once daily for 5 days, consecutively, every cycle |
Inclusion Criteria 1. Subject has completed study participation in Study M11-846 2. Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2. 3. Subject must have adequate hematologic, renal and hepatic function per institutional normal range as follows: • Bone Marrow: Absolute neutrop...
Veliparib is an investigational small molecule being studied for the treatment of solid tumor cancers. It is being evaluated in combination with temozolomide in patients with solid tumors. The drug is currently in Phase 2 clinical development and is not yet approved for any use.
Veliparib is a small molecule being studied in oncology. The specific molecular target of veliparib has not been disclosed in the available information. It is being evaluated in combination with temozolomide for the treatment of solid tumor cancers.
Veliparib is being developed by Abbott Laboratories, which trades under the ticker ABT. The company is conducting clinical trials to evaluate the safety of veliparib in combination with temozolomide in subjects with solid tumors.
Veliparib is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 trial evaluating veliparib in combination with temozolomide in solid tumor cancers has been completed.
Veliparib has one completed clinical trial, NCT01193140, titled "To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors." This Phase 2 study enrolled 24 participants in the United States and was not randomized or blinded.